Procter & Gamble Health マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Milind Thatte

最高経営責任者

₹25.2m

報酬総額

CEO給与比率	100.0%
CEO在任期間	6.6yrs
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	5.4yrs

経営陣の近況

Recent updates

CEO報酬分析

Procter & Gamble Health の収益と比較して、Milind Thatte の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	₹2b
Jun 30 2024	n/a	n/a	₹2b
Mar 31 2024	n/a	n/a	₹2b
Dec 31 2023	n/a	n/a	₹2b
Sep 30 2023	n/a	n/a	₹2b
Jun 30 2023	₹25m	₹25m	₹2b
Mar 31 2023	n/a	n/a	₹2b
Dec 31 2022	n/a	n/a	₹2b
Sep 30 2022	n/a	n/a	₹2b
Jun 30 2022	₹39m	₹39m	₹2b
Mar 31 2022	n/a	n/a	₹2b
Dec 31 2021	n/a	n/a	₹1b
Sep 30 2021	n/a	n/a	₹2b
Jun 30 2021	₹32m	₹32m	₹2b
Mar 31 2021	n/a	n/a	₹2b
Dec 31 2020	n/a	n/a	₹2b
Sep 30 2020	n/a	n/a	₹2b
Jun 30 2020	₹17m	₹26m	₹2b
Mar 31 2020	n/a	n/a	₹2b
Dec 31 2019	n/a	n/a	₹2b
Sep 30 2019	n/a	n/a	₹1b
Jun 30 2019	n/a	n/a	₹1b
Mar 31 2019	n/a	n/a	₹1b
Dec 31 2018	₹20m	₹13m	₹1b

報酬と市場: Milindの総報酬 ($USD 299.46K ) は、 Indian市場 ($USD 364.13K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Milindの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Milind Thatte (55 yo)

6.6yrs

在職期間

₹25,184,000

報酬

Mr. Milind Vasant Thatte, M.Pharm.Sci., M.B.A., has been Managing Director and Executive Director of Procter & Gamble Health Limited (formerly known as Merck Limited) since April 1, 2018. Mr. Thatte had a...

取締役

名称	ポジション	在職期間	報酬	所有権
Milind Thatte	MD & Executive Director	6.6yrs	₹25.18m	データなし
Lokesh Chandak	CFO, Finance Head & Executive Director	1.6yrs	₹27.76m	データなし
Suresh Talwar	Non-Executive Independent Chairman of the Board	40.8yrs	₹2.38m	0.036% ₹ 32.7m
Subramanian Madhavan	Non-Executive Independent Director	3yrs	₹2.13m	データなし
Rani Jadhav	Non-Executive Independent Director	9.8yrs	₹2.20m	データなし
Aalok Agrawal	Non-Executive Director	5.4yrs	データなし	データなし
Seema Sambasivan	Non-Executive Director	1.6yrs	データなし	データなし

5.4yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: 500126の取締役会は経験豊富であると考えられます ( 5.4年の平均在任期間)。

Procter & Gamble Health マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Procter & Gamble Health Limited, Annual General Meeting, Dec 05, 2024

Less than half of directors are independent

Procter & Gamble Health Limited, Annual General Meeting, Nov 30, 2023

Procter & Gamble Health Limited Announces Change in Senior Management Personnel

Less than half of directors are independent

Less than half of directors are independent

Recent updates

First quarter 2025 earnings released: EPS: ₹49.60 (vs ₹39.50 in 1Q 2024)

Procter & Gamble Health Limited to Report Q1, 2025 Results on Nov 04, 2024

Final dividend of ₹60.00 announced

Procter & Gamble Health Limited, Annual General Meeting, Dec 05, 2024

Full year 2024 earnings released: EPS: ₹121 (vs ₹138 in FY 2023)

Procter & Gamble Health Limited to Report Q4, 2024 Results on Aug 21, 2024

Third quarter 2024 earnings released: EPS: ₹28.00 (vs ₹35.70 in 3Q 2023)

Procter & Gamble Health Limited to Report Q3, 2024 Results on May 02, 2024

Second quarter 2024 earnings released: EPS: ₹43.40 (vs ₹46.30 in 2Q 2023)

Procter & Gamble Health Limited Declares Special Dividend for the Financial Year 2023-24, Payable on or Before March 3, 2024

Less than half of directors are independent

Procter & Gamble Health Limited, Annual General Meeting, Nov 30, 2023

Procter & Gamble Health Limited to Report Q1, 2024 Results on Nov 03, 2023

Procter & Gamble Health Limited Recommends Final Dividend,Payable Between November 28, 2023 to December 18, 2023

Full year 2023 earnings released: EPS: ₹138 (vs ₹116 in FY 2022)

Procter & Gamble Health Limited Announces Change in Senior Management Personnel

Procter & Gamble Health Limited to Report Fiscal Year 2023 Results on Aug 23, 2023

Third quarter 2023 earnings released: EPS: ₹35.70 (vs ₹30.80 in 3Q 2022)

Less than half of directors are independent

Less than half of directors are independent

Procter & Gamble Health Limited Recommends an Interim Dividend for the Financial Year 2022-23, Payable on or Before March 05, 2023

Second quarter 2023 earnings released: EPS: ₹46.30 (vs ₹27.00 in 2Q 2022)

Less than half of directors are independent

First quarter 2023 earnings released: EPS: ₹38.30 (vs ₹33.40 in 1Q 2022)

Upcoming dividend of ₹11.50 per share

Procter & Gamble Health Limited to Report Q3, 2022 Results on Nov 09, 2022

Procter & Gamble Health Limited, Annual General Meeting, Nov 23, 2022

Full year 2022 earnings released: EPS: ₹116 (vs ₹107 in FY 2021)

Procter & Gamble Health Limited Recommends Final Dividend for the Financial Year Ended June 30, 2022, Payable Between November 28, 2022 to December 18, 2022

Procter & Gamble Health Limited to Report Fiscal Year 2022 Results on Aug 29, 2022

Procter & Gamble Health Limited Recommends Interim Dividend for the Financial Year 2021-22, payable on or before May 31, 2022

Third quarter 2022 earnings released: EPS: ₹30.80 (vs ₹9.50 in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of ₹130 per share

Full year 2021 earnings released: EPS ₹107 (vs ₹99.87 in FY 2020)

Non-Executive Director Sujay Wasan has left the company

Full year 2021 earnings released: EPS ₹107 (vs ₹99.87 in FY 2020)

Procter & Gamble Health Limited Recommends One-Time Special Dividend for the Financial Year Ended June 30, 2021

Company Secretary & Compliance Officer Preeti Bishnoi has left the company

New 90-day low: ₹6,562

Second quarter 2021 earnings released: EPS ₹40.90 (vs ₹23.02 in 2Q 2020)

New 90-day high: ₹7,315

New 90-day high: ₹7,107

New 90-day high: ₹7,030

First quarter 2021 earnings released: EPS ₹35.70

New 90-day high: ₹5,682

Full year earnings released - EPS ₹99.98

New 90-day high - ₹5,251

Procter & Gamble Health Limited to Report Q2, 2020 Results on Sep 15, 2020

New 90-day high - ₹4,879

New 90-day high - ₹4,402

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34